Tryptophan and 5-Hydroxytryptophan for depression

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2002, Pages

  Shaw, Kelly A ^a   Turner, Jane ^b   Del Mar, Chris ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85097348037     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003198     Document Type: Review

References (97)

1. Thomson J, Rankin H, Ashcroft G, Yates C, McQueen J, Cummings S. The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-Tryptophan and Amitriptyline with placebo. Psychological Medicine 1982;12:741-51.
2. Van Praag HM, Korf J. 5-Hydroxytryptophan as antidepressant: The predictive value of the probenecid test. Psychopharmacology Bulletin 1972;8(4):34-5.
3. Van Praag J, Korf J, Dols L, Schut T. A pilot study of the predictive value of the probenecid test in application of 5-Hydroxytryptophan as antidepressant. Psychopharmacology 1972;25:14-21.
4. Alino J, Gutierrez J, Iglesias M. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depression. A double blind controlled study. International Pharmacopsychiatry 1976;11(1):8-15.
5. Angst J, Woggon B, Schoepf J. The treatment of depression with L-5-Hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Archiv fuer Psychiatrie und Nervenkrankheiten 1977;224(2):175-86.
6. Asheychik R, Jackson T, Baker H, Ferraro R, Ashton T, Kilgore J. The efficacy of L-Tryptophan in the reduction of sleep disturbance and depressive state in alcoholic patients. Journal of Studies on Alcohol 1989;50(6):525-32.
7. Ayuso Gutierrez J, Lopez-Ibor Alino J. Tryptophan and an MAOI (Nialamide) in the treatment of depression. International Pharmacopsychiatry 1971;6(2):92-7.
8. Barker W, Scott J, Eccleston D. The Newcastle chronic depression study: Results of a treatment regime. International Clinical Psychopharmacology 1987;2(3):261-72.
9. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Archives of General Psychiatry 1994;51(4):309-17.
10. Brewerton TD, Mueller EA, Lesem MD, Brandt HA, Quearry B, George DT, et al. Neuroendocrine responses to m-chlorphenylpiperazine and L-tryptophan in bulimia. Archives of General Psychiatry 1992;49(11):852-61.
11. Carroll B, Mowbray R, Davies B. Sequential comparison of L-tryptophan with ECT in severe depression. Lancet 1970;1(654):967-9.
12. Chouinard G, Young S, Annable L, Sourkes T. Tryptophan dosage critical for its antidepressant effect. BMJ 1978;1:1422.
13. Chouinard G, Young SN, Annable L, Sourkes TL. Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatrica Scandinavica 1979;59(4):395-414.
14. Cooper A, Datta S. A placebo controlled evaluation of L-Tryptophan in depression in the elderly. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1980;25(5):386-90.
15. Coppen A, Noguera R. L-tryptophan in depression. Lancet 1970;1(7656):1111.
16. Coppen A, Whybrow B, Nogura R, Maggs R, Prange A Jr. The comparative antidepressant value of L-Tryptophan and Imipramine with and without attempted potentiation by lyothyronine. Archives of General Psychiatry 1972;26:234-41.
17. Whybrow PC, Coppen A, Prange AJ Jr, Noguera R, Bailey JE. Thyroid function and the response to liothyronine in depression. Archives of General Psychiatry 1972;26(3):242-5.
18. Coppen A. Treatment of unipolar depression. Lancet 1976;1(7950):90-1.
19. D'Elia G, Lehmann J, Raotma H. Evaluation of a combination of tryptophan and ECT in the treatment of depression II Biochemical analysis. Acta Psychiatrica Scandinavica 1977;56(4):319-34.
20. d'Elia G, Lehmann J, Raotma H. Evaluation of the combination of tryptophan and ECT in the treatment of depression I Clinical analysis. Acta Psychiatrica Scandinavica 1977;56(4):303-18.
21. d'Elia G, Lehmann J, Raotma H. Influence of tryptophan on memory functions in depressive patients treated with unilateral ECT. Acta Psychiatrica Scandinavica 57[3], 259-68. 1978 1978;57(3):259-68.
22. Dunner DL, Goodwin FK. Effect of L-Tryptophan on brain serotonin metabolism in depressed patients. Archives of General Psychiatry 1972;26(4):364-6.
23. Dunner D, Fieve R. Affective disorder: studies with amine precursors. American Journal of Psychiatry 1975;132(2):180-3.
24. Farkas T, Dunner DL, Fieve RR. L-Tryptophan in depression. Biological Psychiatry 1976;11(3):295-302.
25. Glassman A, Platman S. Potentiation of a monoamine oxidase inhibitor by tryptophan. Journal of Psychiatry Research 1969;7(2):83-8.
26. Harris B. Prospective trial of L-Tryptophan in maternity blues. British Journal of Psychiatry 1980;137:233-5.
27. Herrington R, Bruce A, Johnstone E, Lader M. Comparative trial of L-Tryptophan and amitriptyline in depressive illness. Psychological Medicine 1976;6(4):673-8.
28. Hoes M, Loeffen T, Vree T. Kinetics of L-Tryptophan in depressive patients: A possible correlation between the plasma concentrations of L-Tryptophan and some psychiatric rating scales. Psychopharmacology 1981;75(4):350-3.
29. Hoes MJ, Sijben N. The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. Psychopharmacology 1981;75(4):346-9.
30. Honore P, Moller S, Jorgensen A. Lithium plus L-Tryptophan compared with amitriptyline in endogenous depression. Journal of Affective Disorders 1982;4(1):79-82.
31. Moller SE, Honore P, Larsen OB. Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression. Relation to antidepressant response to amitriptyline and lithium + L-tryptophan. Journal of Affective Disorders 1983;5(1):67-79.
32. Jacobsen F, Sack D, Wehr T, Rogers S, Rosenthal N. Neuroendocrine response to 5-hydroxytryptophan in seasonal affective disorder. Archives of General Psychiatry 1987;44(12):1086-91.
33. Jensen K, Fruensgaard K, Ahlfors UG, Pihkanen TA, Tuomikoski S, Ose E, et al. Tryptophan/imipramine in depression. Lancet 1975;2(7941):920.
34. Kirkegaard C, Moller S, Bjorun N. Addition of L-Tryptophan to electroconvulsive treatment in endogenous depression. Acta Psychiatrica Scandinavica 1978;58(5):457-62.
35. Kline N, Sacks W, Simpson G. Further studies on one day treatment of depression with 5-HTP. American Journal of Psychiatry 1964;121:379-81.
36. Kline N, Shah B. Comparable therapeutic efficacy of tryptophan and imipramine: average therapeutic ratings versus 'true' equivalence. An important difference. Current Therapeutic Research 1973;15(7):484-87.
37. Levitan R, Kennedy S, Shen J, Jindal R, Driver H, Shapiro C. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. Journal of Psychiatry and Neuroscience 2000;25(4):337-347.
38. Lindberg D, Ahlfors UG, Dencker SJ, Fruensgaard K, Hansten S, Jensen K, et al. Symptom reduction in depression after treatment with L-Tryptophan or imipramine. Item analysis of Hamilton rating scale for depression. Acta Psychiatrica Scandinavica 1979;60(3):287-94.
39. Linnoila M, Seppala T, Mattila MJ, Vihko R, Pakarinen A, & Skinner T 3rd. Clomipramine and doxepin in depressive neurosis. Archives of General Psychiatry 1980;37(11):1295-9.
40. Ayuso Gutierrez JL, Lopez Ibor Alino JL, Montejo Iglesias ML. Tryptophan and amitriptyline in the treatment of depression (double blind study) [Triptofano y amitriptilina en el tratamiento de la depresion (estudio doble ciego)]. Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines 1973;1(3):471-6.
41. Lopez Ibor Alino J, Ayuso Gutierrez J, Montejo Iglesias M. Tryptophan and amitriptyline in the treatment of depression: A double blind study. International Pharmacopsychiatry 1973;8:145-51.
42. Lucca A, Lucini V, Catalano M, Smeraldi E. Neural amino acid availability in two major psychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1995;19(4):615-26.
43. MacSweeney D. Treatment of unipolar depression. Lancet 1975;2(7933):510-1.
44. Matussek N, Angst J, Benkert O, Gmur M, Pappousek M, Ruther E, et al. The effect of L-5-Hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro 4-4602) in depressive patients. Advances in Biochemical Psychopharmacology 1974;11(0):399-404.
45. McCance-Katz L, Price L, Charney D, Henninger G. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 1992;108(1-2):93-7.
46. McGrath R, Buckwald B, Resnick E. The effect of L-Tryptophan on seasonal affective disorder. Journal of Clinical Psychiatry 1990;51(4):162-3.
47. Meltzer H, Perline R, Tricou B, Loewe M, Robertson A. Effect of 5-Hydroxytryptophan on serum cortisol levels in major affective disorders II Relation to suicide. Archives of General Psychiatry 1984;41(4):379-87.
48. Meltzer HY, Lowy M, Robertson A, Goodnick P, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate. Archives of General Psychiatry 1984;41(4):391-7.
49. Mendels J, Stinnett J, Burns D, Frazer A. Amine precursors and depression. Archives of General Psychiatry 1975;32(1):22-30.
50. Mendlewicz J, Youdim M. Antidepressant potentiation of 5-Hydroxytryptophan by L-Deprenil in affective illness. Journal of Affective Disorders 1980;2(2):137-46.
51. Murphy D, Baker M, Goodwin F, Miller H, Kotin J, Bunney Jr W. L-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects. Psychopharmacologia 1973;34(1):11-20.
52. Nolen W, van de Putte J, Dijken W, Kamp J. L-5-HTP in depression resistant to reuptake inhibitors. An open comparative study with tranylcypromine. British Journal of Psychiatry 1985;147:16-22.
53. Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1989;13(1-2):155-8.
54. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, et al. Treatment strategy in depression II MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatrica Scandinavica 1988;78(6):676-83.
55. Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1989;13(1-2):155-8.
56. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, et al. Treatment strategy in depression II MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatrica Scandinavica 1988;78(6):676-83.
57. Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: Serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991;24(2):53-81.
58. Prange A Jr, Wilson I, Lynn C, Alltop L, Stikeleather R. L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Archives of General Psychiatry 1974;30(1):56-62.
59. Price L, Mallison R, McDougle C, Pelton G, Henninger G. The neurobiology of tryptophan depletion in depression: Effects of intravenous tryptophan infusion. Biological Psychiatry 1998;43(5):339-47.
60. Quadbeck H, Lehmann E, Tegeler J. Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine. Neuropsychobiology 1984;11(2):111-5.
61. Rao B, Broadhurst A. Tryptophan and depression. BMJ 1976;1:460.
62. Raotma H. Has tryptophan any anticonvulsive effect?. Acta Psychiatrica Scandinavica 1978;57(3):253-8.
63. Rousseau J. Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic performance: a double blind, placebo controlled clinical trial in elderly patients. Clinical Therapeutics 1987;9(3):267-72.
64. Russ M, Ackerman S, Banay-Schwartz M, Shindledecker R, Smith G. Plasma tryptophan to large neutral amino acid ratios in depressed and normal subjects. Journal of Affective Disorders 1990;19:9-14.
65. Salomon R, Delgado P, Licinio J, Krystal J, Hennenger G, Charney D. Effects of sleep deprivation on serotonin function in depression. Biological Psychiatry 1994;36(12):840-6.
66. Seppala T, Linnoila N, Matila M. Psychomotor skills in depressed outpatients treated with L-tryptophan, doxepin, or chlorimipramine. Annals of Clinical Research 1978;10(4):214-21.
67. Shaw D. L-Tryptophan in depression. Lancet 1970;1(7656):1111.
68. Shaw D, Johnson A, Macsweeney D. Tricyclic antidepressants and tryptophan in unipolar affective disorder. Lancet 1972;2(789):1245.
69. Shaw DM, Macsweeney DA, Hewland R, Johnson AL. Tricyclic antidepressants and tryptophan in unipolar depression. Psychological Medicine 1975;5(3):276-8.
70. Smith DF, Stromgren E, Petersen HN, Williams DG, Sheldon W, Angst J, et al. Lack of effect of tryptophan treatment in demented gerontopsychiatric patients: A double-blind, crossover-controlled study. Acta Psychiatrica Scandinavica 1984;70(5):470-7.
71. Steinberg S, Annable L, Young S, Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biological Psychiatry 1999;45(3):313-20.
72. Walinder J, Skott A, Carlsson A, Nagy A, Bjorn-Erik R. Potentiation of the antidepressant action of clomipramine by tryptophan. Archives of General Psychiatry 1976;33(11):1384-9.
73. Walinder J, Skott A, Nagy A, Carlsson A, Roos B. Potentiation of antidepressant action of clomipramine by tryptophan. Lancet 1975;1(7913):984.
74. Worrall EP, Moody JP, Peet M, Dick P, Smith A, Chambers C, et al. Controlled studies of the acute antidepressant effects of lithium. British Journal of Psychiatry 1979;135:255-62.
75. Zarcone V Jr, Berger P, Brodie K, Sack R, Barchas J. The indoleamine hypothesis of depression: An overview and pilot study. Diseases of the Nervous System 1977;38(8):646-53.
76. Zhao H, et al. A self-body double blind clinical study of L-tryptophan and placebo in treated neurosis. Acta Academiae Medicinae Hubei 1989;10(3):256-9.
77. Beckmann H, Kaspers S. Serotonin precursors as an antidepressant: an overview. [Serotonin-Vorstufen als Antidepressiva: eine Ubersicht.]. Fortschritte Neurologie und Psychiatrie 1983;51:176-82.
78. Blackburn W. Eosinophilia myalgia syndrome. Seminars in Arthritis and Rheumatism 1997;26(6):781-4.
79. Bourne H, Bunney W, Colburn R, Davis J, Shaw D, Coppen A. Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hind brains of suicidal patients. Lancet 1968;II(7572):805.
80. Coppen A, Shaw D, Farrel J. Potentiation of the antidepressive effect of a monoamine oxidase inhibitor by tryptophan. Lancet 1963;I:79.
81. D'Elia G, Hanson L, Raotma H. L-tryptophan and 5-hydroxytryptophan in the treatment of depression, a review. Acta Psychiatrica Scandinavica 1978;57(3):239-52.
82. Edgell P. Depression - the commonest disease. Canadian Medical Association Journal 1972;106(2):175-9.
83. Gelenberg A, Gibson C, Wojcik J. Neurotransmitter precursors for the treatment of depression. Psychopharmacology Bulletin 1982;18(1):7-18.
84. Horowitz R, Daniels S. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome. Journal of Rheumatology 1996;46(Suppl 1):81-8.
85. Jorm A, Korten A, Rodgers B, Pollitt P, Jacomb P, Christensen H, et al. Belief systems of the general public concerning the appropriate treatments for mental disorders. Social Psychiatry & Psychiatric Epidemiology 1997;32(8):468-73.
86. Lader M, Herrington R. Drug treatment in psychiatry - psychotropic drugs. In: Praag H, Lader H, Rafaelsen O, Sachar E editor(s). Handbook of Biological Psychiatry. Vol. 5, New York, NY: Marcel Dekker, 1981.
87. Michelson D, Page S, Casey R, Trucksess M, Love L, Milstien S, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. Journal of Rheumatology 1994;21(12):2261-5.
88. Murphy D, Campbell I, Costa J. Current status of the indolamine hypothesis of the affective disorders. In: Lipton M, DiMascio A, Killam R editor(s). Psychopharmacology: A generation of progress. New York, NY: Raven Press, 1978.
89. Pare C, Sandler M. Clinical and biochemical study of a trial of iproniazid in the treatment of depression. Journal of neurology, Neurosurgery & Psychiatry 1959;22:247-51.
90. Pare C, Yeung D, Price K, Stacey R. 5-hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet 1969;II(7612):133-5.
91. Praag H. Management of depression with serotonin precursors. Biological Psychiatry 1981;16(3):291-310.
92. Rousseau J. Effects of a Levo-5-Hydroxytryptophan-Dihydroergocristine combination on depression and neuropsychic performance: A double-blind placebo-controlled clinical trial in elderly patients. Clinical Therapeutics 1987;9(3):267-72.
93. Shaw D, Camps F, Eccleston E. 5-Hydroxytryptamine in the hind brain of depressive suicides. British Journal of Psychiatry 1963;113:1407.
94. Toyo'oka T, Yamazaki T, Tanimoto T, Sato K, Sato M, Toyoda M, et al. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography. Chemical and Pharmaceutical Bulletin 1991;39(3):820-2.
95. Trindade E, Menon D. Selective serotonin reuptake inhibitors (SSRIs) for major depression: Part 1 Evaluation of the clinical literature. CCOHTA. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
96. Wurtman R, Fernstrom J. Control of brain neurotransmitter synthesis by precursor availability and nutritional state. Biochemical Pharmacology 1976;25(15):1691-6.
97. Wurtman R, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacological Reviews 1981;32(4):315-35.